Providers

Provider Resource Center

Research

Revolutionizing Mental Health Treatment: The Emerging Impact of Ketamine in Psychedelic-Assisted Psychotherapy

A comprehensive review explores the groundbreaking role of psychedelic-assisted psychotherapy (PAP) in treating various mental health disorders. The study highlights ketamine's widespread use in over 70 Phase 2 trials for psychiatric conditions, including depression, PTSD, OCD, and substance use disorders. MDMA, gaining FDA breakthrough therapy status for PTSD, shows remarkable success in Phase 2 trials, effectively addressing severe, treatment-resistant PTSD with long-lasting improvements. Psilocybin and LSD, also showing promise, are studied for major depression, existential anxiety, and substance use disorders. The article emphasizes the potential of PAP in offering rapid, effective treatment with significant long-term benefits, challenging conventional psychiatric approaches and contributing to a more holistic understanding of mental health treatment.

Financial Services

Manage your account or make a payment.

Disclaimers

Financing Disclaimer: We offer two financing options for the Uplift Momentum Protocol™ (medical procedure): $325/month for 12 months, with a total cost of $3,900, no down payment, 0% APR, or $1,000 down payment and $237/month for 12 months, with a total cost of $3,844, 0% APR. Approval for both plans is based on internal criteria, including bank account history and a soft credit pull. Payments may be auto-withdrawn monthly. Both plans are subject to a $25 late fee for missed payments and other terms. Cancellation within 3 days of agreement is allowed. Governed by California law and AAA arbitration rules

Individuals showcased on KetamineUplift.com are actors, the content is not reflective of their thoughts, views, or perspectives.

© 2024 Ketamine Uplift | Terms & Conditions | Privacy Policy

Providers

Provider Resource Center

Research

Revolutionizing Mental Health Treatment: The Emerging Impact of Ketamine in Psychedelic-Assisted Psychotherapy

A comprehensive review explores the groundbreaking role of psychedelic-assisted psychotherapy (PAP) in treating various mental health disorders. The study highlights ketamine's widespread use in over 70 Phase 2 trials for psychiatric conditions, including depression, PTSD, OCD, and substance use disorders. MDMA, gaining FDA breakthrough therapy status for PTSD, shows remarkable success in Phase 2 trials, effectively addressing severe, treatment-resistant PTSD with long-lasting improvements. Psilocybin and LSD, also showing promise, are studied for major depression, existential anxiety, and substance use disorders. The article emphasizes the potential of PAP in offering rapid, effective treatment with significant long-term benefits, challenging conventional psychiatric approaches and contributing to a more holistic understanding of mental health treatment.

Disclaimers

Financing Disclaimer: We offer two financing options for the Uplift Momentum Protocol™ (medical procedure): $325/month for 12 months, with a total cost of $3,900, no down payment, 0% APR, or $1,000 down payment and $237/month for 12 months, with a total cost of $3,844, 0% APR. Approval for both plans is based on internal criteria, including bank account history and a soft credit pull. Payments may be auto-withdrawn monthly. Both plans are subject to a $25 late fee for missed payments and other terms. Cancellation within 3 days of agreement is allowed. Governed by California law and AAA arbitration rules

Individuals showcased on KetamineUplift.com are actors, the content is not reflective of their thoughts, views, or perspectives.

Questions?

(310) 280-4440
care@ketamineuplift.com

4640 Admiralty Way
Suite 718A
Marina del Rey, CA 90292

Financial Services

Manage your account or make a payment.

© 2024 Ketamine Uplift | Terms & Conditions | Privacy Policy